In this line, a fusion protein containing PD1 and 4-1BBL has shown to block the PD-1/PD-L1 interaction and to trigger 4-1BB in HCC-specific CD8+ T cells in an HCC animal model, enhancing antitumor immune response and long-lasting tumor regression [71]. Here, CD8A is linked to hepatocellular carcinoma.